Molecular detection of drug resistant polymorphisms in Plasmodium falciparum isolates from Southwest, Nigeria.

OBJECTIVE: Nigeria bears 25% of global malaria burden despite concerted efforts towards its control and elimination. The emergence of drug resistance to first line drugs, artemisinin combination therapies (ACTs), indicates an urgent need for continuous molecular surveillance of drug resistance especially in high burden countries where drug interventions are heavily relied on. This study describes mutations in Plasmodium falciparum genes associated with drug resistance in malaria; Pfk13, Pfmdr1, PfATPase6 and Pfcrt in isolates obtained from 83 symptomatic malaria patients collected in August 2014, aged 1-61 years old from South-west Nigeria.
RESULTS: Two Pfmdr1, N86 and Y184 variants were present at a prevalence of 56% and 13.25% of isolates respectively. There was one synonymous (S679S) and two non-synonymous (M699V, S769M) mutations in the PATPase6 gene, while Pfcrt genotype (CVIET), had a prevalence of 45%. The Pfk13 C580Y mutant allele was suspected by allelic discrimination in two samples with mixed genotypes although this could not be validated with independent isolation or additional methods. Our findings call for robust molecular surveillance of antimalarial drug resistance markers in west Africa especially with increased use of antimalarial drugs as prophylaxis for Covid-19.

Introduction

<span class="Disease">Malaria infects over 220 million <span class="Species">people with at least 405,000 deaths annually, 67% of those deaths occur in children under the age of five, and 94% of deaths according to 2018 World Health Organization data occurred in Africa [1]. Drug resistance of malaria parasites to previously efficacious first line chemotherapies, chloroquine (CQ) and sulfadoxine-pyrimethamine (SP), in sub-Saharan Africa (sSA), led to replacement with artemisinin combination therapies (ACT), and complete removal of CQ [1, 2]. A single point mutation K76T, in codons 72–76 of the chloroquine resistance transporter gene (Pfcrt) has been the main cause of resistance to CQ [3, 4], while mutations in the dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) were responsible for SP resistance in parasites [5, 6].

<span class="Species">P. falciparum has also developed resistance to ACTs, which combines a fast-acting artemisinin (ART) derivative with a long-lasting partner such as Lumefantrine, Mefloquine or Amodiaquine. ACT resistance is widespread in the Greater Mekong subregion (GMS) in southeast Asia [1, 7]. Resistance to ART and its derivatives have been confirmed to be associated with mutations in Kelch-13 gene (pfk13). Mutations in pfk13 have been reported in GMS, Guyana, Rwanda, and Tanzania [1]. In sSA, pfk13 mutations are yet to be associated with partial or complete ART-resistant parasite isolates, and ACT efficacy still remains very high. However, there have been increasing case reports of ACT failures, or delayed parasite clearance within Africa suggesting the need to investigate the factors that might be responsible [8, 9]. Mutations in Pfmdr1 on codons 86, 184, 1246 and copy number amplifications have also been linked to susceptibility to drugs including ACTs. P. falciparum sarco-endoplasmic reticulum calcium-ATPase (SERCA) type protein encoded by a gene PfATPase6 has been described to modulate the susceptibility of parasites to ART. PfATPase6 protein of P. falciparum has therefore been suggested to be a target of ARTs [10-12].

Molecular surveillance of drug resistance associated mutations, especially to ACTs is particularly relevant in Africa which bears >  90% of the <span class="Disease">deaths globally. This study describes the molecular prevalence of mutations in the drug resistant genes Pfk13, Pfmdr1, PfATPase6 and Pfcrt from P. falciparum clinical samples in Southwest Nigeria, where Arthemeter Lumefantrine has been the main first line ACT for malaria treatment over the last 15 years.

Main text

Materials and methods

Study site

This study was carried out in August 2014 in two communities—Badagry (Lagos <span class="Gene">State) and Alajue (Ede, Osun <span class="Gene">State). Badagry (6° 25′ N 2° 53′ E), is a coastal town with an area of 170 m2 and a human population of 241,093 (NPC, 2006) that borders the Republic of Benin. Alajue village (7° 40′ N 4° 30′ E), is an ancient Yoruba town with a total area of 130 m2 and a human population of 159,866 (NPC, 2006). Both towns are located in the south western part of Nigeria, with similar environmental conditions, occupation and lifestyle of the people.

Sampling

A total of 83 symptomatic <span class="Disease">malaria <span class="Species">patients were recruited for this study. Following informed consent of the participants, parent or guardian, they were tested with malaria rapid diagnostic test (RDT) kit and 2 ml blood samples were collected into RNAlater. Dried blood spots (DBS) of each sample was made on 3MM Whatman filter paper.

Nucleic acid extraction

DNA from DBS was extracted using the Qiagen Mini <span class="Gene">Kit (Qiagen) according to manufacturer’s instructions and stored at minus 20 °C until needed. Total RNA was isolated from whole blood stored in RNAlater using PureLink™ RNA Mini <span class="Gene">Kit (Invitrogen) following the manufacturer’s instructions.

Plasmodium falciparum molecular detection

DNA from DBS of each sample was used for molecular speciation of <span class="Species">P. falciparum by nested PCR through amplification of the 18S rRNA following e<span class="Gene">stablished protocols [13]. Nest 1 amplified a large part of the 18S rRNA common to the Plasmodium genus, while the Nest 2 amplified a region in the genus specific for that species of Plasmodia. Differentiation of the species was based on amplicon band size with P. falciparum having a size of 205 bp. PCR fragments were detected and sized on the QIAXCEL automated electrophoresis system.

Quantitative PCR

To determine the gene expression levels of Pf<span class="Gene">k13 and PfATPase, total RNA was treated to remove genomic DNA by digesting with 2 µl of DNaseI (Fermentas) and 5 µl of reaction buffer, incubated at 37 °C for 30 min and inactivated with 5 µl, 25 mM <span class="Chemical">EDTA, 65 °C for 10 min. RNA purity and concentration were determined using a NanoDrop 1000TM (Thermo Scientific). cDNA was synthesised using the RNA Reverse Transcriptase kit (Invitrogen). Synthesized cDNA was quantified by qPCR on a CFX 96 (Bio-Rad) with the following cyclic conditions: 95 °C, 10 min, 49 cycles of 95 °C, 15 s and 60 °C for 90 s. Relative fold increase of specific mRNA transcripts in samples was compared to P. falciparum (3D7) wildtype control, normalised using the 18S rRNA housekeeping gene. Expression levels were calculated using 2−ΔΔCt method. Data was analysed using at least 3 independent experiments.

pfk13 and PfATPase genotyping

Alleles of Pf<span class="Gene">k13 propeller domain polymorphisms (<span class="Mutation">Y493H, R539T, I543T, C580Y), and PfATPase6 (S679S, M699V, S769M) associated with delayed clearance were determined by Taqman allelic discrimination and sequencing and list of primers used provided in Additional file 1: (Tables S1, 2). For each sample a working Master Mix was prepared to include 1× of Taqman Universal PCR Master Mix (Life Technologies), 300 nM of the forward and reverse primers, 200 nM of each allele specific probe (Additional file 1: Table S2) and at least 5 ng of DNA from DBS in 25 µl reaction volume. Amplification was done on the Bio-Rad CFX96 real-time thermocycler set to detect fluorescent emissions for 6-carboxyfluorescein (6-FAM) (mutant) and hexachloro-6-carboxyfluorescein (HEX) (wild type). Each SNP was amplified in a thermocycle of 50 °C for 2 min, 10 min of initial template denaturation and enzyme activation at 95 °C followed by 50 cycles of 92 °C for 15 s and 60 °C for 1 min. Allelic discrimination analysis was performed with the Bio-Rad CFX manager with parameters set to subtract background and correct for fluorescent drift prior to clustering of wild or mutant amplicons. All PCRs included DNA from P. falciparum 3D7 as wildtype control.

Sequencing

Pf<span class="Gene">k13, PfATPase6, Pfcrt and Pfmdr1 amplicons were purified from a 0.8% <span class="Chemical">agarose gel and subjected to cycle sequencing using BigDye V3.1 (details in supplementary methods section). Sequencing was done on ABI3130XL DNA analyser.

Data analysis

Descriptive statistics was carried out in Microsoft Excel 2010. Sequence alignment was done on <span class="Gene">CLC Main Workbench Version 6.7.1 and translation of nucleotide sequence to amino acid sequences and editing were done using MEGA 7.0.4 software. A P-value of ≤ 0.05 was considered statistically significant. Transcript level determination and allelic discrimination analyses were done with the Bio-Rad CFX96 manager software (Additional file 2).

Results

Demographics

In this study, 83 <span class="Species">patients, 36 (43.37%) male and 47 (56.63%) females presenting with symptoms of <span class="Disease">malaria were recruited for the study (Additional file 1: Table S3). The age distribution was as follows; 6 (0–5 years), 34 (6–19 years) 25 (20–35  years) and 18 were > 35 years.

mRNA transcript levels and polymorphisms in Pfk13 and PfATPase6 genes

Following confirmation of all RDT positive samples as <span class="Species">P. falciparum positive by PCR, we carried out gene expression, detecting only wild type Pf<span class="Gene">k13 transcript in samples. Relatively low levels of PfATPase6 transcript was also detected with both wild and mutant strains identified in the population (Fig. 1). Probe-specific allelic discrimination, detected both wild type and mutant PfATPase6 alleles at known drug resistance SNPs (Fig. 2). For Pfk13 C580Y locus, mixed alleles (both 580C and 580Y) were suspected in 2 isolates but the mutant type variant was not confirmed by Sanger sequencing of amplicons against the reference strain P. falciparum 3D7. K13 sequence identified eight non-synonymous SNPs in Pfk13, but all in single isolates. A deletion variant A557 was identified in 3.61% of isolates sequenced (Additional file 1: Table S4).

Fig. 1

Messenger RNA transcript levels for Pfk13 and PfATPase using 2−ΔΔCt. Total RNA was isolated from whole blood preserved in RNALater, reverse transcribed to cDNA in order to measure gene expression profiles

Fig. 2

Allelic discrimination of wild and mutant genes in parasite samples (a) Pfk13 SNP580 and (b) PfATPase SNP402. DNA from dried blood spots (DBS) were extracted and used for TaqMan allele discrimination assays. Blue points depict wild type alleles, green for mixed allele calls and orange for mutant variants. Untyped reactions are shown in black

Messenger RNA transcript levels for Pf<span class="Gene">k13 and PfATPase using 2−ΔΔCt. Total RNA was isolated from whole blood preserved in RNALater, reverse transcribed to cDNA in order to measure gene expression profiles

Allelic discrimination of wild and mutant genes in parasite samples (a) Pf<span class="Gene">k13 SNP580 and (b) PfATPase SNP402. DNA from dried blood spots (DBS) were extracted and used for TaqMan allele discrimination assays. Blue points depict wild type alleles, green for mixed allele calls and orange for mutant variants. Untyped reactions are shown in black

Distribution and prevalence of PfATPase6, Pfmdr 1 and Pfcrt polymorphisms

Sequence analysis of PfATPase6 revealed 3 SNPs, one synonymous and two non-synonymous mutations (Additional file 1: Table S4). The ACT resistance related SNP (S769) was present in 3.6% of samples. Pfmdr1 wildtype N86 allele was present in 56% of isolates sequenced. Pfmdr1 Y184 was at much lower prevalence of 13.25% (Additional file 1: Table S4). Pfcrt 72–76 variants were translated, and haplotypes inferred. The CVIET haplotype associated with <span class="Chemical">CQ resistance had a prevalence of 45%, while the wildtype CVMNK was found in 55% of isolates from the population (Fig. 3).

Fig. 3

Prevalence of Pfcrt polymorphisms in Lagos, Nigeria. Samples were amplified for codons 72–76 using DNA from dried blood spots, and amplicons subjected to Sanger sequencing to identify the haplotypes. CVMNK = Cysteine-Valine-Methionine-Asparagine-Lysine and CVIET = Cysteine-Valine-Isoleucine-Glutamic acid-Threonine at codons 72–76 of the chloroquine resistance transporter gene (Pfcrt)

Discussion

Chemotherapy is one of the main <span class="Disease">malaria control strategies implemented by the National <span class="Disease">Malaria Control program in Nigeria. Today, it is mostly based on first line Artemisinin based combination therapy that was introduced into Nigeria in 2005 following the withdrawal of CQ and SP due to widespread resistance. Hence, there is need to continuously monitor drug resistance and genetic markers that are associated with reduced drug efficacy. This study characterized drug resistance associated polymorphism in four different P. falciparum drug resistance genes; Pfcrt, Pfmdr1, PfATPase6 and Pfk13 that have been implicated in reduced ACT efficacy [2, 3, 9, 14]. As expression of mutated genes is needed for generating the resistance phenotype, the allele specific mRNA transcript levels of Pfk13 and PfATPase6 were also determined.

Most isolates expressed the wild type Pf<span class="Gene">k13 while both the wild and mutant PfATPase6 variants were expressed by different strains. Though Pf<span class="Gene">k13 C580Y mutant allele was suspected in two mixed infections, only wildtype mRNA was detected. These mutant variants might have been from a minority strain whose mRNA expression might have been masked by predominant Pfk13 wildtype parasites in the infections. In the absence of repeated detection and confirmation by sequencing, the possibility of the detected Pfk13 C580Y mutants being as a result of contamination cannot be ruled out. ACTs have been in use for 15 years in Nigeria, and the classical South East Asian Pfk13 artemisinin resistance markers are rare in Africa. However, the possibility of the Pfk13 580Y resistance mutations is a call for concern, requiring further sampling and analysis of this population. The Pfk13 C580Y mutant is the most prevalent SNP associated with reduction in parasite susceptibility to ACTs. Only few cases of delayed clearance of malaria after ACT treatment have been reported in Africa and the C580Y is almost completely absent. A recent ACT therapeutic efficacy study with patients from the same populations detected persistent parasites 3 days post treatment but no Pfk13 artemisinin resistance associated mutants [15]. Future enlarged studies including in vivo and in vitro assessments, genetically characterising local parasite isolates may throw light on any possible emergence of tolerance to ACT components. Though genetic epidemiology and in vitro forward genetic approaches have clearly implicated C580Y and other Pfk13 mutations in delayed parasite clearance [16, 17], the artemisinin resistance phenotype and associated molecular mechanisms may be different in African parasites lacking these Pfk13 variants. However, a recent report from Rwanda confirmed de novo local emergence and spread of the Pfk13 R561H artemisinin resistance associated variant, though clinical cure rate remained > 95% [18]. Other Pfk13 haplotypes containing mutations at positions A578S and V581F, close to the C580Y mutation, are known to circulate in Africa and could have emerged prior to the introduction of ACTs [19]. Overall, any molecular indicators of resistance to artemisinins should be taken seriously and carefully monitored to prevent selection and spread of fit resistant parasites across Africa, which heavily relies on drugs against high levels of infection and morbidity.

We also detected polymorphisms of PfATPase6, the <span class="Mutation">R37K, <span class="Mutation">A630S, I898I found in Brazil, double mutation E431K, A623E in Senegal, and H243Y in Central Africa. The PfATPase6 S769 SNP we detected has been widely reported as a potential molecular marker for P. falciparum resistance to artemether [20]. This SNP is found within the cytoplasmic N (nucleotide binding) domain close to the conserved hinge, which in many species is important for structural transitions in the PfATPase cycle, calcium binding and release [14].

Other well-known characterized mutations in drug resistant genes such as Pfmdr1- <span class="Mutation">N86Y and Y184F, and pfcrt- CVIET haplotype were also detected. Polymorphisms of Pfmdr1 (N86Y, Y184F, S1034C, N1042D, and D1246Y) and copy number amplifications modulate resistance to quinolones and other ACT partner drugs. They have been associated with reduced efficacy of artemether- lumefantrine/mefloquine combinations [21]. Artemether-Lumefantrine is the most common ACT combination in Africa and Nigeria. It selects for wildtype N86 and mutant Y184, as shown for other populations in West Africa [22].

Surprisingly a high prevalence of the CVIET haplotype was recorded despite the withdrawal of <span class="Chemical">CQ from the population almost 10 years prior to this study. The high prevalence (45%) observed for Pfcrt-76T resistance marker in southwest Nigeria is however lower than those reported from the south-eastern part of the country, where prevalence was as high as 75% [23]. Lumefantrine selects for wildtype Pfcrt K76, reversing CQ resistance that is strongly linked to the CVIET haplotype [3]. This reversal to the CQ susceptible CVMNK wild type haplotype following CQ withdrawal has been reported across many malaria endemic regions; in China [24], Tanzania [25], Kenya [26] and Malawi [27], or following malaria decline as observed in Ghana [28]. Exception are only seen in countries like Ethiopia (29) were CQ is still being administered to treat P. vivax, maintaining CQ pressure on the parasite to retain the resistant haplotypes. In Nigeria, CQ remains accessible through private drug suppliers together with amodiaquine, both of which could be slowing the reversal of the resistant haplotype in the population.

This study provides a molecular profile of the drug resistance genes in <span class="Disease">malaria parasites from South Western Nigeria, highlighting the need for continuous and broader surveillance for antimalarial resistance of this high malaria prevalent population.

Limitations

Our limited study locations and sample size is not sufficient to detect emerging resi<span class="Gene">stance loci that may be at low frequencies in the populations. Due to limited availability of sampled DNA and RNA, we were unable to repeat the detection of the suspected <span class="Mutation">C580Y mutant or validate its presence using sequencing approaches.

Additional file 1: Table S1. List of primers and cycling conditions for amplification. Table S2. Taqman primers and probes. Table S3. Demographics of respondents. Table S4. Description of Pf<span class="Gene">k13, PfATPase and Pfmdr1 polymorphisms. Figure S1. Allelic discrimination of <span class="Gene">K13 single nucleotide polymorphisms (SNPs).

Additional file 2. Allelic discrimination.